Its presence in bodily fluids such as serum and cerebrospinal fluid sparks hope for its utility in early stroke diagnosis. GFAP has demonstrated high specificity (up to 85-95%) for distinguishing ischemic strokes from hemorrhagic strokes due to its release following astrocyte damage, which is more pronounced in hemorrhagic strokes. The gene discussed is GFAP; the disease is hemorrhagic stroke.